好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Diagnostic Delay and Perceptions of Multiple Sclerosis in Hispanic/Latinx Patients
Multiple Sclerosis
P7 - Poster Session 7 (5:00 PM-6:00 PM)
1-001

Evaluate and compare time to diagnosis and perceptions of Multiple sclerosis (MS) in Hispanic/Latinx (H/Lx) and non-Hispanic/Latinx patients.

MS is a chronic immune-mediated disease, and socioeconomically disadvantaged individuals have a higher risk of morbidity and mortality. Research links social determinants of health to MS in Black and H/Lx patients. A study at our MS center found Black patients were significantly more likely than White patients to experience diagnostic delays. The timing of initiating MS therapy is crucial as it helps slow down disease progression and prevent relapses. 

Phone surveys were conducted on MS patients seen at the Georgetown MS center. Initial phone surveys were conducted on H/Lx patients followed by the selection of a control group of non-Hispanic/Latinx White patients matched based on birth year interval, sex, and neurologists. The total sample size was 70, 35 per group. Data collected include self-reported race/ethnicity, time of first symptom, first neurologist visit, and MS diagnosis. Additionally, MS perceptions were collected by asking an open-ended question addressing significant events that led to symptom onset.

The overall results revealed a greater median time delay in H/Lx compared to non-Hispanic/Latinx patients. Notably, an assessment delay between the onset of the symptoms to first neurology visit was observed within the H/Lx group, with a median time delay of 15 compared to 2. Moreover, H/Lx patients were more likely to attribute their MS onset to emotions/stress, contrasting with Non-Hispanic White patients linking it to environmental factors and family history. Limitations include sample size and recall bias.

The observed discrepancy in diagnostic delay might be attributed to lower awareness of symptoms, reduced care-seeking behavior, social determinants of health and potential implicit bias among primary care providers referring H/Lx patients. Diagnostic delays in H/Lx offer insights into MS disparities, highlighting the need for targeted interventions in underserved patients.

Authors/Disclosures
Jerusalem Wogayehu
PRESENTER
Miss Wogayehu has nothing to disclose.
Luis G. Manrique, MD (MedStar Georgetown University Hospital) Dr. Manrique has nothing to disclose.
Benjamin J. Osborne, MD, FAAN (Medstar Georgetown University Hospital) Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Osborne has received publishing royalties from a publication relating to health care.
Robert K. Shin, MD, FAAN Dr. Shin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Shin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sandoz. Dr. Shin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Shin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BMS. Dr. Shin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Shin has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for TG Therapeutics. Dr. Shin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Shin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen.